THE EFFECTIVENESS OF INFLIXIMAB IN CHILDREN WITH IBD, DEPENDING ON THE LEVEL OF CIRCULATING CYTOKINES AND THE CONCENTRATION OF THE DRUG
- 作者: Radygina T.1, Illarionov A.1, Gerasimova D.1, Anushenko A.1, Komakh Y.2, Potapov A.1, Petrichuk S.1, Fisenko A.1
-
隶属关系:
- National Medical Research Center for Children’s Health
- The S. Fyodorov Eye Microsurgery Federal State Institution
- 期: 卷 22, 编号 4 (2019)
- 页面: 1531-1533
- 栏目: ORIGINAL ARTICLES
- URL: https://journals.rcsi.science/1028-7221/article/view/119689
- DOI: https://doi.org/10.31857/S102872210007080-3
- ID: 119689
如何引用文章
全文:
详细
作者简介
T. Radygina
National Medical Research Center for Children’s Health
编辑信件的主要联系方式.
Email: Radygina.TV@nczd.ru
Ph.D. (Medicine), Senior Research Associate, Laboratory of Experimental Immunology and Virology,
Moscow
俄罗斯联邦A. Illarionov
National Medical Research Center for Children’s Health
Email: fake@neicon.ru
PhD student of the Gastroenterological department with hepatological group,
Moscow
俄罗斯联邦D. Gerasimova
National Medical Research Center for Children’s Health
Email: fake@neicon.ru
intern oftheLaboratory of Experimental Immunology and Virology,
Moscow
俄罗斯联邦A. Anushenko
National Medical Research Center for Children’s Health
Email: fake@neicon.ru
pediatrician of the Gastroenterological department with hepatological group,
Moscow
俄罗斯联邦Y. Komakh
The S. Fyodorov Eye Microsurgery Federal State Institution
Email: fake@neicon.ru
PhD, Head of the Transplantology and Cellular Biology Laboratory,
Moscow
俄罗斯联邦A. Potapov
National Medical Research Center for Children’s Health
Email: fake@neicon.ru
Moscow 俄罗斯联邦
S. Petrichuk
National Medical Research Center for Children’s Health
Email: fake@neicon.ru
PhD, MD (Biology), Professor, Main Research Associate, Laboratory of Experimental Immunology and Virology,
Moscow
俄罗斯联邦A. Fisenko
National Medical Research Center for Children’s Health
Email: fake@neicon.ru
Head of the National Medical Research Center for Children’s Health,
Moscow
俄罗斯联邦参考
- Ungar B., Levy I., Yavne Y., Yavzori M., Picard O., Fudim E., Loebstein R., Chowers Y., Eliakim R., Kopylov U., Ben-Horin S. Optimizing Anti-TNF-α Therapy: Serum Levels ofInfliximab and Adalimumab Are Associated With Mucosal Healing in Patients WithInflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2016;14:550–7.
- Hanauer S. B., Wagner C. L., Bala M., Mayer L., Travers S., Diamond R. H., Olson A., Bao W., Rutgeerts P. Incidence and importance of antibody responsesto infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol 2004;2:542–53. treatment in Crohn’s disease.